HSD11B2 and apparent mineralocorticoid excess: Patients carrying HSD11B2 homozygous mutations resulting in little or no 11βHSD2 activity usually present with severe phenotypes of AME in early childhood, whereas heterozygous patients with mutations resulting in partial 11βHSD2 activity may present with mild forms of AME in late adolescence or early adulthood [10, 22].